Boston Trust Walden Corp Purchases 229,885 Shares of Jazz Pharmaceuticals PLC $JAZZ

Boston Trust Walden Corp boosted its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 129.1% in the second quarter, Holdings Channel.com reports. The firm owned 407,897 shares of the specialty pharmaceutical company’s stock after buying an additional 229,885 shares during the quarter. Boston Trust Walden Corp’s holdings in Jazz Pharmaceuticals were worth $43,286,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Envestnet Portfolio Solutions Inc. increased its holdings in shares of Jazz Pharmaceuticals by 170.9% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 11,834 shares of the specialty pharmaceutical company’s stock valued at $1,256,000 after acquiring an additional 7,465 shares in the last quarter. Ellis Investment Partners LLC increased its holdings in shares of Jazz Pharmaceuticals by 13.2% during the second quarter. Ellis Investment Partners LLC now owns 6,045 shares of the specialty pharmaceutical company’s stock valued at $641,000 after acquiring an additional 707 shares in the last quarter. CWM LLC increased its holdings in shares of Jazz Pharmaceuticals by 197.1% during the second quarter. CWM LLC now owns 3,740 shares of the specialty pharmaceutical company’s stock valued at $397,000 after acquiring an additional 2,481 shares in the last quarter. Blue Trust Inc. increased its holdings in shares of Jazz Pharmaceuticals by 6.8% during the second quarter. Blue Trust Inc. now owns 3,152 shares of the specialty pharmaceutical company’s stock valued at $334,000 after acquiring an additional 200 shares in the last quarter. Finally, Callan Family Office LLC bought a new position in shares of Jazz Pharmaceuticals during the second quarter valued at $619,000. 89.14% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on JAZZ shares. Morgan Stanley raised their price target on Jazz Pharmaceuticals from $163.00 to $167.00 and gave the company an “overweight” rating in a report on Wednesday, September 24th. The Goldman Sachs Group raised their price target on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a “buy” rating in a report on Friday, August 29th. Truist Financial raised their price target on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a “buy” rating in a report on Thursday, August 28th. Needham & Company LLC reiterated a “buy” rating and issued a $202.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, August 28th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Jazz Pharmaceuticals in a report on Tuesday, July 15th. They issued a “buy” rating and a $152.00 price objective for the company. Fourteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $178.93.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ opened at $133.81 on Wednesday. The company has a market capitalization of $8.12 billion, a price-to-earnings ratio of -19.88, a PEG ratio of 8.30 and a beta of 0.28. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. The stock has a 50-day moving average of $126.67 and a 200 day moving average of $115.79. Jazz Pharmaceuticals PLC has a one year low of $95.49 and a one year high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The firm had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $1.05 billion. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The company’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same period in the previous year, the business posted $5.30 earnings per share. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, sell-side analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of the firm’s stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total value of $771,720.00. Following the transaction, the director directly owned 429,973 shares of the company’s stock, valued at approximately $55,303,127.26. This trade represents a 1.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold 11,500 shares of company stock valued at $1,525,280 over the last 90 days. Company insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.